Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
15.79
+1.29 (8.90%)
At close: May 4, 2026, 4:00 PM EDT
15.60
-0.19 (-1.20%)
After-hours: May 4, 2026, 6:35 PM EDT
Entrada Therapeutics Market Cap
Entrada Therapeutics has a market cap or net worth of $576.91 million as of May 4, 2026. Its market cap has increased by 106.02% in one year.
Market Cap
576.91M
Enterprise Value
332.14M
1-Year Change
106.02%
Ranking
Category
Stock Price
$15.79
Market Cap Chart
Since the IPO on October 29, 2021, Entrada Therapeutics's market cap has increased from $251.01M to $576.91M, an increase of 129.83%. That is a compound annual growth rate of 20.28%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 1, 2026 | 529.78M | 43.70% |
| Dec 31, 2025 | 368.66M | -39.78% |
| Dec 31, 2024 | 612.16M | 21.70% |
| Dec 29, 2023 | 503.01M | 18.72% |
| Dec 30, 2022 | 423.70M | -20.71% |
| Dec 31, 2021 | 534.36M | 112.88% |
| Oct 29, 2021 | 251.01M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Adlai Nortye | 606.80M |
| Crescent Biopharma | 595.46M |
| Zevra Therapeutics | 594.10M |
| AgomAb Therapeutics NV | 589.96M |
| Altimmune | 586.48M |
| Prothena Corporation | 580.86M |
| Ginkgo Bioworks Holdings | 576.83M |
| ProKidney | 567.69M |